Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

  title={Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions},
  author={Lyndsey L. Anderson and Nathan L. Absalom and Sarah V. Abelev and Ivan K Low and Peter T. Doohan and Lewis J Martin and Mary Chebib and Iain S. McGregor and Jonathon C Arnold},
  pages={2224 - 2234}
Cannabidiol (CBD) has been approved by the US Food and Drug Administration (FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox‐Gastaut syndrome. However, the intrinsic anticonvulsant activity of CBD has been questioned due to a pharmacokinetic interaction between CBD and a first‐line medication, clobazam. This recognized interaction has led to speculation that the anticonvulsant efficacy of CBD may simply reflect CBD augmenting clobazam exposure. The present… 

Citalopram and Cannabidiol

Clinicians should be vigilant around the possibility of treatment-emergent adverse effects when CBD is introduced to patients taking these antidepressants.

Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps

The most striking gaps in knowledge are the efficacy and optimal dose of CBD for adults with focal epilepsies, the long-term safety of CBD use, and strategies to improve access to CBD for people living with epilepsy.

Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials

The best clinical evidence to date is provided that CBD exerts therapeutic effects in patients with epilepsy that are independent of its interaction with CLB, and greater antiseizure effects, and a greater burden of adverse effects, are observed when CBD is combined withCLB.

Interactions between cannabidiol and Δ9‐tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome

The Scn1a+/− mouse model of Dravet syndrome is utilized to examine whether the presence of Δ9‐THC modulates the anticonvulsant efficacy of CBD.

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials

To assess the efficacy and safety profile of add‐on cannabidiol (CBD) in patients with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS) on clobazam and in the overall population of four

Commentary on: Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions

The authors properly indicate that an increased risk for sudden unexpected death is observed in patients with Dravet syndrome; therefore the aim of their experimental study to evaluate the effectiveness of the combined treatment of cannabidiol with clobazam is fully justified.

Prescribing medicinal cannabis

Clinical trial evidence generally supports the efficacy of THC in treating conditions such as chronic pain, spasticity in multiple sclerosis, anorexia and cachexia, Tourette syndrome and chemotherapyinduced nausea and vomiting.



Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children, and it is predicted a drug–drug interaction.

Interactions between cannabidiol and commonly used antiepileptic drugs

To identify potential pharmacokinetic interactions between the pharmaceutical formulation of cannabidiol (CBD; Epidiolex) and the commonly used antiepileptic drugs (AEDs) through an open‐label safety

Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes

CBD offers patients with DS and LGS a new treatment option for refractory seizures and is well tolerated, the first cannabis-derived medication with approval from the US Food and Drug Administration.

The pharmacokinetics and the pharmacodynamics of cannabinoids.

The limited availability of applicable pharmacokinetic and pharmacodynamic information highlights the need to initiate prescribing cannabis medicines using a 'start low and go slow' approach, carefully observing the patient for desired and adverse effects.

Clobazam and Its Active Metabolite N-desmethylclobazam Display Significantly Greater Affinities for α2- versus α1-GABAA–Receptor Complexes

GABAA-receptor binding affinities of CLB, N-desmethylclobazam (N-CLB), CLN, and ZOL were characterized with native receptors from rat-brain homogenates and on cloned receptors from HEK293 cells transfected with combinations of α (α1, α2, α3, or α5), β2, and γ2 subtypes, demonstrating the high preference for α1 receptors.

Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

  • E. Perucca
  • Medicine, Psychology
    Journal of epilepsy research
  • 2017
There is now class 1 evidence that adjunctive use of CBD improves seizure control in patients with specific epilepsy syndromes, for the first time, according to currently available information.

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

This study provides Class I evidence that for children with Dravet syndrome, CBD resulted in more AEs than placebo but was generally well-tolerated.

Benzodiazepine pharmacology and central nervous system-mediated effects.

For any patient taking a BZD, the prescribing physician must carefully evaluate the risks and benefits, and higher-risk patients require careful considerations, as Clinically appropriate use of BZDs requires prudence and the understanding of pharmacology.

Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome

CBD effectively reduced seizures and autistic-like social deficits in a well-validated mouse genetic model of Dravet syndrome, a severe childhood epilepsy disorder caused by loss-of-function mutations in the brain voltage-gated sodium channel NaV1.1.